Laboratory Values in the H63D Spectrum and in Patients suffering from Oshtoran Syndrome seem to be More Susceptible to Error – A Report on the H63D Conference 2026 and Its Embedding in Laboratory Medicine

H63D syndrome is a distinct clinical phenotype based on a homozygous mutation of the HFE gene and is not hemochromatosis from which it is to be distinguished from hemochromatosis, as the underlying pathology lies not in ferritin-bound iron overload but in the formation of non-transferrin-bound iron (NTBI) causing the creation and irrevocable formation of highly toxic NTBI which triggers oxidative microinflammatory processes, particularly in the substantia nigra, the basal ganglia, and parenchymal tissues, with a broad spectrum of neurological, cardiac, hepatic, endocrine, and immunological manifestations. (1) A hitherto rarely systematically addressed dimension of this challenge has now been highlighted at the H63D Conference 2026.